Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Harry Ehrlich who wrote (1188)	3/2/1998 11:03:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 2173

Big boy buyers and sellers. Do you really think that the buyer knew that JNJ was pulling out! I'm pretty sure that he would have no problem buying a million shares at $3 tomorrow.

To: Harry Ehrlich who wrote (1188)	3/3/1998 7:55:00 AM
From: tonyt	Respond to of 2173

Of course. If you believe that the 1.6 million was just big block buying/selling, I have a bridge in Brooklyn to sell you :-)

To: Harry Ehrlich who wrote (1188)	3/3/1998 7:57:00 AM
From: Henry Niman	Respond to of 2173

Since the price didn't move on the 1.6 million shares, I would assume that buyers and sellers were rather evenly matched and as I said last night, I don't think that the buyers thought JNJ would pull support.

To: Harry Ehrlich who wrote (1188)	3/3/1998 8:03:00 AM
From: tonyt	Read Replies (1) \| Respond to of 2173

I wonder what the sellers thought? Anyone who would think that a stock as thinly traded as AMLN can have 10 times normal volume on just big block buying/selling is at the very least naive about the stock market.

To: Harry Ehrlich who wrote (1188)	3/3/1998 8:14:00 AM
From: Henry Niman	Respond to of 2173

Joe Kernan just gave a review of AMLN's recent history. He noted that they had been on CNBC before and after the company said the the August results were promising, the price fell from something like $16 to below $10. He also noted that it was difficult to pull the plug on a promising drug, which is why some companies can go through Phase III and then not get approved. He said this time AMLN's partner, JNJ, pulled the plug early. He implied that things were not good, but fell just short of indicating that the price would tank this morning (which is my take on the segment if the listener reads between the lines).